Follow The Filings

CTNM Contineum Therapeutics

Contineum Therapeutics earnings company data as of 11:59 AM ET 10/23

Limited consensus data for this ticker (thin coverage or data-plan limits). Dates may be company-announced rather than sell-side consensus. Calendar and recent prints remain the primary lens when available.

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 29 Oct EPS — — —
Rev — — —

Insider trades

Open-market buys and sales by CTNM's executives, directors and 10% owners in the last 12 months, from their Form 4s

All CTNM insider trades
  • None no insider bought on the open market
  • None no sales outside a trading plan
  • $1.9M sold by 3 insiders under 10b5-1 plans
  1. Carmine N. Stengone CEO
    Planned sale
    $41K 2,500 shares at $16.46 13% of stake
    Traded Sep 8 Filed Sep 8
    ↗
  2. Carmine N. Stengone CEO
    Planned sale
    $40K 2,500 shares at $16.01 13% of stake
    Traded Aug 3 Filed Aug 3
    ↗
  3. Daniel S. Lorrain Chief Scientific Officer
    Planned sale
    $17K 1,040 shares at $16.00 0.8% of stake
    Traded Jul 8–9 Filed Jul 10
    ↗
  4. Carmine N. Stengone CEO
    Planned sale
    $40K 2,500 shares at $16.00 13% of stake
    Traded Jul 8 Filed Jul 8
    ↗
  5. Daniel S. Lorrain Chief Scientific Officer
    Planned sale
    $595K 37,179 shares at $15.99 22% of stake
    Traded Jun 30–Jul 1 Filed Jul 2
    ↗
  6. Tim Watkins CMO & Head of Development
    Planned sale
    $174K 10,833 shares at $16.02 55% of stake
    Traded Jun 30 Filed Jul 1
    ↗
  7. Carmine N. Stengone CEO
    Planned sale
    $160K 10,000 shares at $16.01 37% of stake
    Traded Jun 30 Filed Jul 1
    ↗
  8. Daniel S. Lorrain Chief Scientific Officer
    Planned sale
    $55K 4,170 shares at $13.16 2.9% of stake
    Traded Jun 1 Filed Jun 1
    ↗
  9. Daniel S. Lorrain Chief Scientific Officer
    Planned sale
    $55K 4,170 shares at $13.12 2.8% of stake
    Traded May 1 Filed May 1
    ↗
  10. Daniel S. Lorrain Chief Scientific Officer
    Planned sale
    $56K 4,170 shares at $13.43 2.7% of stake
    Traded Apr 6 Filed Apr 6
    ↗
  11. Daniel S. Lorrain Chief Scientific Officer
    Planned sale
    $63K 4,170 shares at $15.01 2.7% of stake
    Traded Mar 2 Filed Mar 2
    ↗
  12. Tim Watkins CMO & Head of Development
    Planned sale
    $54K 3,611 shares at $15.02 100% of stake
    Traded Mar 2 Filed Mar 2
    ↗
  13. Carmine N. Stengone CEO
    Planned sale
    $114K 7,100 shares at $16.02 32% of stake
    Traded Feb 24–25 Filed Feb 26
    ↗
  14. Daniel S. Lorrain Chief Scientific Officer
    Planned sale
    $130K 8,124 shares at $16.02 4.9% of stake
    Traded Feb 24–25 Filed Feb 26
    ↗
  15. Daniel S. Lorrain Chief Scientific Officer
    Planned sale
    $1,600 100 shares at $16.00 0.1% of stake
    Traded Feb 19 Filed Feb 20
    ↗

Also filed in the last 12 months, not counted as buying or selling: 20 option exercises.

SEC filings

Recent issuer filings from EDGAR, 20 shown.

Filed Form Detail Links
SCHEDULE 13G — Filing Doc
8-K 8.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 7.01,9.01 Filing Doc
8-K 5.07 Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
DEF 14A Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
DEFA14A Filing Doc
SCHEDULE 13G — Filing Doc
8-K 2.02,8.01,9.01 Filing Doc
10-K Filing Doc
424B5 Filing Doc

Source: SEC EDGAR submissions, updated about 20 hours ago. All on EDGAR

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.